All In Biotech

Drug Trial Radar · NCT02988973

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia

A Phase 3 Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia

Last checked: Nov 19, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 334 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

334

Actual

Start

Jan 12, 2017

Primary completion

Sep 13, 2019

Study completion Mar 26, 2020

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
Collaborators
Kyntra Bio
First posted
Dec 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

Conditions

  • Chronic Kidney Disease

Interventions

  • roxadustatDrug

    Oral administration

  • DADrug

    Subcutaneous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the average Hemoglobin (Hb)Time frame: Baseline and Weeks 18 to 24

Locations

66 sites in 1 country. Site status is shown where the registry gives one.

  • Site JP00014

    Fukui, Japan

  • Site JP00033

    Fukuoka, Japan

  • Site JP00065

    Fukuoka, Japan

  • Site JP00032

    Hiroshima, Japan

  • Site JP00039

    Hiroshima, Japan

  • Site JP00045

    Kyoto, Japan

  • Site JP00018

    Nagano, Japan

  • Site JP00068

    Nagano, Japan

  • Site JP00026

    Niigata, Japan

  • Site JP00034

    Ōita, Japan

  • Site JP00055

    Okayama, Japan

  • Site JP00056

    Osaka, Japan

  • Site JP00061

    Osaka, Japan

  • Site JP00010

    Toyama, Japan

  • Site JP00009

    Kasugai, Aichi-ken, Japan

  • Site JP00030

    Nagoya, Aichi-ken, Japan

  • Site JP00051

    Nagoya, Aichi-ken, Japan

  • Site JP00021

    Toyohashi, Aichi-ken, Japan

  • Site JP00003

    Sakura, Chiba, Japan

  • Site JP00038

    Matsuyama, Ehime, Japan

  • Site JP00044

    Matsuyama, Ehime, Japan

  • Site JP00008

    Kitakyushu, Fukuoka, Japan

  • Site JP00013

    Kitakyushu, Fukuoka, Japan

  • Site JP00040

    Kitakyushu, Fukuoka, Japan

  • Site JP00057

    Kitakyushu, Fukuoka, Japan

  • Site JP00042

    Kurume, Fukuoka, Japan

  • Site JP00041

    Tajimi, Gifu, Japan

  • Site JP00002

    Maebashi, Gunma, Japan

  • Site JP00037

    Hatsukaichi, Hiroshima, Japan

  • Site JP00050

    Kure, Hiroshima, Japan

  • Site JP00049

    Aasahikawa, Hokkaido, Japan

  • Site JP00007

    Sapporo, Hokkaido, Japan

  • Site JP00064

    Sapporo, Hokkaido, Japan

  • Site JP00022

    Amagasaki, Hyōgo, Japan

  • Site JP00066

    Nishinomiya, Hyōgo, Japan

  • Site JP00052

    Hitachi, Ibaraki, Japan

  • Site JP00017

    Kasama, Ibaraki, Japan

  • Site JP00028

    Koga, Ibaraki, Japan

  • Site JP00053

    Naka, Ibaraki, Japan

  • Site JP00023

    Sashima-gun, Ibaraki, Japan

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.